Overall Score

Profitability Returns

Gross margin remains strong at 74.2% with EBIT margin at 10.7%, supporting solid operating profitability.

Returns are respectable but not elite, with ROIC at 9.5% and ROE at 11.5%.

Net margin is 7.1%, indicating moderate bottom-line conversion despite high gross margins.

Financial Strength

Balance sheet remains very strong with a current ratio of 4.12 and quick ratio of 3.68.

Leverage is low, with debt-to-equity at 0.06 and net debt to EBITDA at -1.26, indicating net cash.

Interest coverage is extremely high at 604.0x, reflecting minimal near-term solvency risk.

Growth Reinvestment

Reinvestment remains modest, with capex at just 1.1% of revenue and capex-to-operating cash flow at 12.5%.

R&D spend is low at 2.9% of revenue, suggesting limited internal growth investment intensity.

Working capital is healthy at $119.3M, but the operating cycle of 113.1 days and cash conversion cycle of 81.0 days imply moderate capital tied up in operations.

Valuation

Valuation is reasonable at 1.36x EV/sales and 10.8x EV/EBITDA, which is not demanding for a profitable medical device business.

Free cash flow yield of 5.0% and earnings yield of 4.6% suggest fair but not cheap pricing.

Price-to-free-cash-flow of 19.9x indicates the market is still assigning a meaningful growth premium.